EC approves XTANDI™ (enzalutamide) for Metastatic Hormone-Sensitive Prostate Cancer
The European Commission has approved Astellas’ XTANDI™ (enzalutamide) for men with metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Japanese multinational pharmaceutical company
Read more